Showing 3641-3650 of 6035 results for "".
- AcuFocus Submits US Premarket Approval Application to the FDA for Its IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-submits-us-premarket-approval-application-to-the-fda-for-its-ic-8-small-aperture-iol/2478903/AcuFocus announced that it has submitted a premarket approval (PMA) application to the FDA for its IC-8 small aperture IOL. The IC-8 IOL is an aspheric monofocal lens that features an embedded filter with a small central aperture. Using wavefront-filtering, small aperture optics, the lens is desi
- Re-Vana Therapeutics Names New Members to the Executive Teamhttps://modernod.com/news/re-vana-therapeutics-names-new-members-to-the-executive-team/2478897/Re-Vana Therapeutics announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a br
- Ophtec: Tiny ID Matrix Code Enables Fast Delivery of Premium IOLshttps://modernod.com/news/ophtec-tiny-id-matrix-code-enables-fast-delivery-of-premium-cataract-iols/2478885/Ophtec announced it has recently integrated a laser marking technology in the production process of its premium cataract IOLs. A micro ID matrix code is imprinted in the IOLs loop junctions by the laser. Using this code, special scanners can identify the IOL
- GenSight Biologics Announces Publication of Results from Lumevoq Phase 1/2a Clinical Trial REVEAL in BioDrugshttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/GenSight Biologics announced that the journal BioDrugs has published results from REVEAL, the phase 1/2a clinical trial that evaluated the safety of Lumevoq gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the ph
- Reichert Technologies Debuts New Website Designed to Improve Customer Experiencehttps://modernod.com/news/reichert-technologies-debuts-new-website-designed-to-improve-customer-experience/2478866/Reichert Technologies has announced the launch of a newly redesigned website with an improved user experience. The new website, available at the same address—reichert.com—features a s
- Oculus and Myopia Profile Aim to Increase Knowledge on Myopiahttps://modernod.com/news/oculus-and-myopia-profile-aim-to-increase-knowledge-on-myopia/2478860/Myopia Profile and Oculus have commenced a partnership to increase ECP knowledge and clinical confidence in measurement and interpretation of axial length in myopia. Specific educational content, research summaries and case studies will be developed, to be housed on MyopiaProfile.com and shared a
- Palatin Technologies Announces Filing of International Patent Application for Lead Compound for Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-filing-of-international-patent-application-for-lead-compound-for-dry-eye-disease/2478853/Palatin Technologies announced the filing of an international patent application under the Patent Cooperation Treaty (PCT) directed to the composition of PL9643 and a related family of melanocortin agonist peptides. Palatin recently reported positive results in its phase 2 study of PL9643
- Eye Health America Acquires Three Optometric Practices in the Pee Dee Region of South Carolinahttps://modernod.com/news/eye-health-america-acquires-three-optometric-practices-in-the-pee-dee-region-of-south-carolina/2478837/Eye Health America (EHA) has added three optometric practices into its business family: David Hamill, OD, and First Vision Group (FVG); Mark Vinson, OD and Vision Care (VC); and David Johnson, OD and Marlboro Eye Care Associates (MECA). All have been providing eye care in Florence, Marion and Ben
- Santen Launches Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-launches-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2478828/Santen EMEA has announced the launch of Ducressa, a fixed dose combination of levofloxacin/dexamethasone eye drops solution indicated for the prevention and treatment of inflammation, and the prevention of infection a
- Eyedaptic Augmented Reality Visual Aid Granted Patent to Further Aid Those With Macular Degeneration and Low Visionhttps://modernod.com/news/eyedaptic-augmented-reality-visual-aid-granted-patent-to-further-aid-those-with-macular-degeneration-and-low-vision/2478789/Eyedaptic announced it was recently granted the first out of nine pending patents. Additionally, Eyedaptic launched an Equity Crowdfunding Campaign to increase awareness and introduce their advanced visual aid solution to an expanding list of stakeholders in the eye care and technology communitie